Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

Blocking RANKL with denosumab to protect ovarian follicles

Official title: Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis

Run by Regionshospitalet Viborg, Skive · NCT07546552 · Data updated 2026-11-12

This trial will test whether giving denosumab, a drug that blocks RANKL, can help protect follicle development in women with infertility who are undergoing assisted reproduction.

More Osteoporosis trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment100 (estimated)
SponsorRegionshospitalet Viborg, Skive
Academic / other
Drugs / interventionsdenosumab
Locations1 site (Skive, Midt Jylland)
StatusRecruiting
StartedAugust 1, 2025
Main results expectedMarch 15, 2028
Study endsMarch 15, 2028
Registry record updatedApril 22, 2026
Trial IDNCT07546552 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women age 18 or older with a normal AMH who can give informed consent and who have not had autotransplanted ovarian tissue are the intended participants.

Probably not a fit

Patients who have had autotransplanted ovarian tissue or who have very low ovarian reserve are unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will give participants either denosumab or a placebo (PBS) and monitor ovarian follicle development during treatment. Outcomes will be tracked using hormone measurements, ultrasound assessments of follicle counts, and assisted reproduction cycle results where applicable. The protocol targets mechanisms of RANKL signaling that preclinical work suggests influence early folliculogenesis. The aim is to determine whether RANKL inhibition can reduce the impact of ovarian aging on fertility.

Why it matters

Potential benefit: If successful, this approach could slow ovarian aging and increase egg yield and success rates in assisted reproduction.

How similar studies have gone: Preclinical rodent and human tissue studies have shown effects of RANKL inhibition on gonadal function and denosumab is an approved anti-RANKL drug for osteoporosis, but clinical use to modify folliculogenesis in women is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female in the age of 18 or above, Normal AMH-value, able to give concent

Exclusion Criteria:

* Patients who have had autotransplanted ovarian tissue

Where it's running

  • Regionshospitalet, Skive, Midt Jylland 7800
    Skive, Midt Jylland, Denmark
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.